Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Tivicay. Always confirm against the full prescribing information.
100 interactions
Abemaciclib
Abemaciclib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Level 2 evidence
Abiraterone
Abiraterone may increase the hepatotoxic activities of Dolutegravir.
Level 2 evidence
Abrocitinib
The serum concentration of Dolutegravir can be increased when it is combined with Abrocitinib.
Level 2 evidence
Acarbose
Acarbose may increase the hepatotoxic activities of Dolutegravir.
Level 2 evidence
Acetaminophen
Acetaminophen may increase the hepatotoxic activities of Dolutegravir.
Level 2 evidence
Acetazolamide
Acetazolamide may increase the hepatotoxic activities of Dolutegravir.
Level 2 evidence
Acitretin
Acitretin may increase the hepatotoxic activities of Dolutegravir.
Level 2 evidence
Acyclovir
The excretion of Acyclovir can be decreased when combined with Dolutegravir.
Level 2 evidence
Adagrasib
The serum concentration of Dolutegravir can be increased when it is combined with Adagrasib.
Level 2 evidence
Adenine
The metabolism of Dolutegravir can be decreased when combined with Adenine.
Level 2 evidence
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Dolutegravir.
Level 2 evidence
Afatinib
Afatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Tivicay (Dolutegravir Sodium) has 772 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Tivicay (Dolutegravir Sodium) has 12 major, 483 moderate, and 277 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Tivicay. Always confirm against the full prescribing information.